Display options
Cite
Lurins J, Lurina D, Tretjakovs P, et al. Increased serum chemerin level to predict early onset of aortic valve stenosis. Biomed Rep. 2017;8(1):31-36doi: 10.3892/br.2017.1010.
Lurins, J., Lurina, D., Tretjakovs, P., Mackevics, V., Lejnieks, A., Rapisarda, V., & Baylon, V. (2018). Increased serum chemerin level to predict early onset of aortic valve stenosis. Biomedical reports, 8(1), 31-36. https://doi.org/10.3892/br.2017.1010
Lurins, Juris, et al. "Increased serum chemerin level to predict early onset of aortic valve stenosis." Biomedical reports vol. 8,1 (2018): 31-36. doi: https://doi.org/10.3892/br.2017.1010
Lurins J, Lurina D, Tretjakovs P, Mackevics V, Lejnieks A, Rapisarda V, Baylon V. Increased serum chemerin level to predict early onset of aortic valve stenosis. Biomed Rep. 2018 Jan;8(1):31-36. doi: 10.3892/br.2017.1010. Epub 2017 Nov 02. PMID: 29387388; PMCID: PMC5768061.
Copy Download .nbib Format: NLM
Share it on

Biomed Rep. 2018 Jan;8(1):31-36. doi: 10.3892/br.2017.1010. Epub 2017 Nov 02.

Increased serum chemerin level to predict early onset of aortic valve stenosis.

Biomedical reports

Juris Lurins, Dace Lurina, Peteris Tretjakovs, Vitolds Mackevics, Aivars Lejnieks, Venerando Rapisarda, Vincenzo Baylon

Affiliations

  1. Department of Doctoral Studies, Riga Stradins University, Riga, LV 1007, Latvia.
  2. Zemgale Health Centre, Jelgava, LV 3001, Latvia.
  3. Faculty of Medicine, Department of Human Physiology and Biochemistry, Riga Stradins University, Riga, LV 1007, Latvia.
  4. Faculty of Medicine, Department of Internal Diseases, Riga Stradins University, Riga, LV 1002, Latvia.
  5. Department of Clinical and Experimental Medicine, Occupational Medicine, University Hospital 'Policlinico-Vittorio Emanuele', University of Catania, I-95123 Catania, Italy.
  6. Newton Lewis Institute-ISR - Life Science Park, San Gwann 3000, Malta.

PMID: 29387388 PMCID: PMC5768061 DOI: 10.3892/br.2017.1010

Abstract

Inflammation appears to be the cause of aortic valve (AoV) stenosis and identification of predictive biomarkers is therefore imperative. The aim of the current study was to evaluate the potential role of serum chemerin and fibroblast growth factor-21 (FGF-21) in the pathogenesis of the disease. A total of 102 patients were selected based on certain criteria and divided into an aortic stenosis group and a control group. Patients with AoV stenosis were subdivided into three groups depending on the severity according to the echocardiography criteria: Aortic jet velocity, Vmax (m/sec); mean pressure gradient, PG (mmHg); aortic valve area (AVA), cm

Keywords: FGF-21; aortic valve stenosis; biomarkers; chemerin

References

  1. J Am Coll Cardiol. 2001 Oct;38(4):1078-82 - PubMed
  2. PLoS One. 2014 Feb 03;9(2):e87102 - PubMed
  3. J Exp Med. 2008 Apr 14;205(4):767-75 - PubMed
  4. Trends Endocrinol Metab. 2010 Nov;21(11):660-7 - PubMed
  5. J Exp Med. 2003 Oct 6;198(7):977-85 - PubMed
  6. PLoS One. 2010 Dec 29;5(12):e15534 - PubMed
  7. PLoS One. 2012;7(6):e40043 - PubMed
  8. Diabetes. 2008 May;57(5):1246-53 - PubMed
  9. Acta Pharmacol Sin. 2011 May;32(5):573-80 - PubMed
  10. Br J Dermatol. 2013 Apr;168(4):749-55 - PubMed
  11. Peptides. 2014 Dec;62:150-4 - PubMed
  12. BMC Cardiovasc Disord. 2014 Apr 30;14:56 - PubMed
  13. Clin Endocrinol (Oxf). 2010 Mar;72(3):342-8 - PubMed
  14. Cytokine. 2015 May;73(1):176-80 - PubMed
  15. Eur J Endocrinol. 2009 Aug;161(2):339-44 - PubMed
  16. Int J Mol Sci. 2015 Oct 09;16(10):23745-59 - PubMed
  17. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2852-61 - PubMed
  18. Regul Pept. 2011 Jun 7;168(1-3):69-72 - PubMed
  19. Cleve Clin J Med. 2003 May;70(5):471-7 - PubMed
  20. Toxicol Appl Pharmacol. 2016 Jan 1;290:43-53 - PubMed
  21. Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):331-8 - PubMed
  22. Clin Exp Hypertens. 2014;36(5):326-32 - PubMed
  23. J Biol Chem. 2007 Sep 21;282(38):28175-88 - PubMed
  24. Lancet. 2011 Oct 29;378(9802):1547-59 - PubMed
  25. Obes Rev. 2013 Mar;14(3):245-62 - PubMed
  26. J Hum Hypertens. 2013 Jun;27(6):397-9 - PubMed
  27. Arch Cardiovasc Dis. 2012 Oct;105(10):465-7 - PubMed
  28. Regul Pept. 2012 Jan 10;173(1-3):55-9 - PubMed
  29. Clin Rheumatol. 2015 Mar;34(3):419-27 - PubMed
  30. Expert Rev Cardiovasc Ther. 2013 Feb;11(2):239-50 - PubMed
  31. Biochem Biophys Res Commun. 2010 Jan 22;391(4):1762-8 - PubMed
  32. Inflamm Res. 2015 Feb;64(2):85-95 - PubMed
  33. Nat Commun. 2013;4:2019 - PubMed
  34. Peptides. 2014 Nov;61:7-11 - PubMed
  35. J Viral Hepat. 2010 Sep;17(9):661-7 - PubMed
  36. JACC Cardiovasc Interv. 2008 Apr;1(2):127-8 - PubMed
  37. Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2454-9 - PubMed
  38. Metabolism. 2013 Nov;62(11):1513-21 - PubMed
  39. Eur J Endocrinol. 2013 Oct 01;169(5):547-57 - PubMed
  40. Diabetes Res Clin Pract. 2012 May;96(2):196-203 - PubMed
  41. Biochem Biophys Res Commun. 2007 Nov 3;362(4):1013-8 - PubMed
  42. J Biochem. 2011 Feb;149(2):121-30 - PubMed
  43. J Am Coll Cardiol. 2008 Apr 8;51(14):1327-36 - PubMed
  44. J Immunol. 2010 Sep 15;185(6):3728-39 - PubMed
  45. Front Endocrinol (Lausanne). 2015 Aug 31;6:133 - PubMed
  46. Inflamm Bowel Dis. 2010 Apr;16(4):630-7 - PubMed
  47. J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S18-24 - PubMed
  48. Eur Heart J. 2005 Jul;26(13):1333-41 - PubMed
  49. Exp Mol Pathol. 2015 Apr;98(2):208-13 - PubMed
  50. J Immunol. 2012 Jul 15;189(2):956-67 - PubMed
  51. PLoS One. 2013;8(2):e57802 - PubMed

Publication Types